Variations on a theme: The alternate translocations in APL

Leukemia

Volumn 16, Issue 10, 2002, Pages 1927-1932

  Redner, R L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

APL; NPM RAR; NUMA RAR; PLZF RAR; PMLL RAR; STAT5b RAR

Indexed keywords

ARSENIC TRIOXIDE; DNA; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; STAT5B PROTEIN; ZINC FINGER PROTEIN;

AGED; CANCER RECURRENCE; CHROMOSOME 11Q; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 5Q; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 5; DIMERIZATION; DRUG MECHANISM; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW;

EID: 0036798277     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402720     Document Type: Review

References (61)

1. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage-Pochitaloff M. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hematologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000; 96: 1297-1308.
2. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
3. Kakizuka A, Miller WJ, Umesono K, Warrell RJ, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
4. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997; 90: 4876-4885.
5. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. Embo J 1993; 12: 1161-1167.
6. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, Degos L, Zelent A, Waxman S, Chomienne C. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 1994; 91: 1178-1182.
7. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
8. Evans R. The steroid and thyroid hormone receptor superfamily. Nature 1988; 240: 889-895.
9. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH Jr. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083-1094.
10. Jansen JH, Lowenberg B. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein. Semin Hematol 2001; 38: 37-41.
11. Corey SJ, Locker J, Oliveri DR, Shekhtar-Levin S, Redner RE, Penchansky L, Gollin SM. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia with atypical features. Leukemia 1994; 8: 1350-1353.
12. Redner RE, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
13. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103: 127-140.
14. Hummel JL, Wells RA, Dube ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene 1999; 18: 633-641.
15. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, Gao YR, Niu C, Cao Q, Gu BW, Zhu YM, Gu J, Hu J, Yan H, Shen ZX, Chen Z, Chen SJ. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia 2001; 15: 1359-1368.
16. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
17. Redner RL, Corey SJ, Rush EA. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 1997; 11: 1014-1016.
18. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997; 17: 109-113.
19. Arnould C, Philippe C, Bourdon V, Gregoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999; 8: 1741-1749.
20. Cigudosa JC, Calasanz MJ, Odero MD, Marin J, Bengoechea E, Gullon A. A variant t(14;17) in acute promyelocytic leukemia. Positive response to retinoic acid treatment. Cancer Genet Cytogenet 1995; 80: 160-161.
21. Miura I, Nishinari T, Hashimoto K, Nimura T, Miura S, Miura AB. Translocation (8;17)(p21;q21), a possible variant of t(5;17), in acute promyelocytic leukemia. Cancer Genet Cytogenet 1994; 72: 75-77.
22. Schwartz JG, Clare N, Hansen K, Britton H, Manhoff L. Acute promyelocytic leukemia: report of a variant translocation, t(1;17). Cancer Genet Cytogenet 1986; 20: 89-93.
23. Yamada K, Sugimoto E, Amano M, Imamura Y, Kubota T, Matsumoto M. Two cases of acute promyelocytic leukemia with variant translocations: the importance of chromosome No. 17 abnormality. Cancer Genet Cytogenet 1983; 9: 93-99.
24. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108: 165-170.
25. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
26. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP. Distinct interactions of PML-RAR-alpha and PLZF-RAR-alpha with co-repressors determine differential responses to RA in APL. Nature Genet 1998; 18: 126-135.
27. Chen SJ, Zhu YJ, Tong JH, Dong S, Huang W, Chen Y, Xiang WM, Zhang L, Li XS, Qian GQ, Wang GD, Chen Z, Larsen Q, Berger R. Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. Blood 1991; 78: 2696-2701.
28. Shekhter-Levin S, Gollin SM, Kaplan SS, Redner RL. Involvement of the MLL and RARalpha genes in a patient with acute monocytic leukemia with t(11;17)(q23;q12). Leukemia 2000; 14: 520-522.
29. Hauksdottir H, Privalsky ML. DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ 2001; 12: 85-98.
30. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417-428.
31. Grignani F, Dematteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone cleacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
32. Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
33. Redner RL, Chen JD, Rush EA, Li H, Pollock SL. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood 2000; 95: 2683-2690.
34. So CW, Dong S, So CK, Cheng GX, Huang QH, Chen SJ, Chan LC. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. Leukemia 2000; 14: 77-83.
35. Dong S, Qiu J, Patel K, Brinkley WR, Mancini MA, Tweardy DA. The coiled-coil domain of NuMA-RAR alpha is essential for its oncogenic activities and localization to NuMA sites within the nucleus. Blood 2001; 98: 559a.
36. Dong S, Tweardy DJ. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002; 99: 2637-2646.
37. Maurer AB, Wichmann C, Gross A, Kunkel H, Heinzel T, Ruthardt M, Groner B, Grez M. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 2002; 99: 2647-2652.
38. Dyck JA, Gerd GG, Miller WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyt-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343.
39. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonesca M, Lammond A, Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RARa in acute promyelocytic leukemia cells. Cell 1994; 76: 345-356.
40. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20: 7234-7242.
41. Redner RL, Schlesinger KW, Pollock SL, Watkins SC. The t(5;17) APL fusion protein NPM-RAR does not alter PML localization. Blood 1997; 90 (Suppl.): 321a.
42. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen JY, Staub A, Garnier JM, Mader S, Chambon P. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992; 68: 377-395.
43. Mader S, Chen JY, Chen Z, White J, Chambon P, Gronemeyer H. The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificites of the DNA binding domains. EMBO J 1993; 12: 5029-5041.
44. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Naar AM, Kim SY, Boutin JM, Glass CK, Rosenfeld MG. RXR beta: a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 1991; 67: 1251-1266.
45. Redner RL, Rush EA, Pollack SA. RXR binding is essential for NPM-RAR inhibition of U937 differentiation. Blood 1998; 92 (Suppl. 1): 213a.
46. Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, Pelicci PG. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J 1996; 15: 4949-4958.
47. Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Nervi C, Pelicci PG. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. Oncogene 1999; 18: 6313-6321.
48. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5: 821-830.
49. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heterodimeric interactions with RXR. EMBO J 1993; 12: 3171-3182.
50. Licht JD, Shaknovich R, English MA, Melnick A, Li JY, Reddy JC, Dong S, Chen SJ, Zelent A, Waxman S. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene 1996; 12: 323-336.
51. Warrell RJ, Frankel SR, Miller WJ, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med 1991; 324: 1385-1393.
52. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 2001; 20: 7257-7265.
53. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20: 7146-7153.
54. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci USA 1999; 96: 15103-15108.
55. Sitterlin D, Tiollais P, Transy C. The RAR alpha-PLZF chimera associated with acute promyelocytic leukemia has retained a sequence-specific DNA-binding domain. Oncogene 1997; 14: 1067-1074.
56. He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP. Two critical hits for promyelocytic leukemia. Mol Cell 2000; 6: 1131-1141.
57. Redner RL, Rush EA, Wang AS. Divergent roles for the NPM-RAR and RAR-NPM t(5;17) APL fusion proteins in inhibition of myeloid differentiation. Blood 2001; 98 (Suppl. 2): 154b.
58. Tenen DG. Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 2001; 15: 688-689.
59. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
60. Doucas V, Brockes JP, Yaniv M, de Thé H, Dejean A. The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc Nat Acad Sci USA 1993; 90: 9345-9349.
61. Fakih MG, Redner RL. Acute promyelocytic leukemia t(5;17) fusion product NPM-RAR down-regulates AP-1 activity in the presence of ATRA. Proc AACR 2001.